Immunophenotypic aberrancies in acute lymphoblastic leukemia from 282 Iraqi patients

Jalal, Sana Dlawar; Al-Allawi, Nasir; Doski, A. A. S. Al

doi:10.1111/ijlh.12716

Cited by 11 publications

(13 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Asynchronous co-expression of CD34 and CD20 was seen in 44% (33/75) (Table 1) cases. Seegmiller (2009) also reported such an asynchronous expression in 37.5% (75/200) cases of B-ALL cases while Sharma (2016) and Jalal (2017) an asynchronous dual expression of CD34 and CD20 in 12% cases. Firstly, such asynchronous expression of early and late antigens defies normal antigenic evolution of B-cell precursors and thus can be useful to differentiate blasts from hematogones in evaluating MRD.…”

Section: Discussionmentioning

confidence: 89%

CD34 is not Expressed by Blasts in a Third of B-ALL Patients and its Negativity is associated with Aberrant Marker Expression: A Retrospective Analysis

Garg

Gupta

Kotru

2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Background: CD34 antigen is expressed by early hematopoietic progenitor cells and acute leukemia cells. Its expression is associated with good prognosis in acute myeloid leukemia. Literature is sparse on its prognostic significance in B-acute lymphoblastic leukemia (B-ALL) especially from India. Hence the present study was undertaken to analyse the frequency of CD34 expression in B-ALL in Indian patients and determine its prognostic significance by associating with other prognostic markers and aberrant antigen expression. Methods: Seventy-five B-ALL patients diagnosed by flow cytometry over a period of 3½ year were studied. Correlation of CD34 expression was studied with gender, age, total leucocyte count (TLC), French-American-British (FAB) morphological type, immuno-phenotypic markers, cytogenetics and minimal residual disease. Differences between groups were evaluated using Student's T-test for quantitative data and Chi-square test/Fishers exact T-test for qualitative variables. P value <0.05 was considered significant. Results: CD34 was positive in 66.66% (50/75) cases while it was negative in rest (33.33%; 25/75) cases. CD13, CD33, CD5, CD7 and CD11b were more frequently expressed in CD34 negative B-ALL (p=0.025). No association of CD34 expression was found with gender, age, TLC, FAB morphological type, other immune-phenotypic markers, MRD and cytogenetics studied. Conclusions: The expression of CD34 does not associate with known prognostic markers in B-ALL. However, absence of CD34 is associated with aberrant immunophenotypic expression (myeloid + T-cell antigens) in these patients. Larger studies with larger sample size and more extensive immunophenotypic panel needs to be done in Indian setup to confirm these findings.

show abstract

Section: Discussionmentioning

confidence: 89%

CD34 is not Expressed by Blasts in a Third of B-ALL Patients and its Negativity is associated with Aberrant Marker Expression: A Retrospective Analysis

Garg

Gupta

Kotru

2021

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…Immunophenotypic analysis of 282 ALL patients conducted in Iraq by Sana D. Jalal et al. revealed that 80.5% (194/241) of B-ALL patient samples and 95.1% (39/41) of T-ALL patient samples expressed CD38 ( 40 ). Jutta Deckert et al.…”

Section: Cd38 Expression In Healthy Tissues and Diseasesmentioning

confidence: 99%

Targeting CD38 for acute leukemia

Zhong

Ma²

2022

Front. Oncol.

View full text Add to dashboard Cite

Acute leukemia (AL) is a hematological malignancy, and the prognosis of most AL patients hasn’t improved significantly, particularly for relapsed or refractory (R/R) AL. Therefore, new treatments for R/R adult acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are urgently necessary. Novel developments have been made in AL treatment, including target and immune therapies. CD38 is one of the targets due to its high expression in many hematological malignancies, including multiple myeloma, ALL and a subset of AML. Consequently, targeting CD38 therapies, including CD38 monoclonal antibodies (mAbs), bispecific antibodies, and CAR-T cell therapy, exhibit promising efficacy in treating multiple myeloma without significant toxicity and are being explored in other hematological malignancies and nonhematological diseases. Herein, this review focuses on targeting CD38 therapies in ALL and AML, which demonstrate sound antileukemic effects in acute leukemia and are expected to become effective treatment methods.

show abstract

“…An important role in homogenizing and standardizing the flow-cytometry-based detection of MRD in acute leukemia was proposed by the European BIOMED-1 Concerted Action, which defined protocols for identifying normal subsets of B, T, and myeloid cells in bone marrow, the starting point for subsequent studies of the aberrant immunophenotypes involved in ALL. These efforts provided an excellent basis for standardized flow cytometric MRD studies in multicenter international treatment protocols for precursor-B-cell ALL and T-cell ALL patients, first by defining a normal pattern, and second, by establishing pathology-based patterns and optimal reagent combinations [137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154].…”

Section: Measurable Residual Diseasementioning

confidence: 99%

Approach to the Adult Acute Lymphoblastic Leukemia Patient

Sas

Moisoiu

Teodorescu

et al. 2019

JCM

View full text Add to dashboard Cite

During recent decades, understanding of the molecular mechanisms of acute lymphoblastic leukemia (ALL) has improved considerably, resulting in better risk stratification of patients and increased survival rates. Age, white blood cell count (WBC), and specific genetic abnormalities are the most important factors that define risk groups for ALL. State-of-the-art diagnosis of ALL requires cytological and cytogenetical analyses, as well as flow cytometry and high-throughput sequencing assays. An important aspect in the diagnostic characterization of patients with ALL is the identification of the Philadelphia (Ph) chromosome, which warrants the addition of tyrosine kinase inhibitors (TKI) to the chemotherapy backbone. Data that support the benefit of hematopoietic stem cell transplantation (HSCT) in high risk patient subsets or in late relapse patients are still questioned and have yet to be determined conclusive. This article presents the newly published data in ALL workup and treatment, putting it into perspective for the attending physician in hematology and oncology.

show abstract

Immunophenotypic aberrancies in acute lymphoblastic leukemia from 282 Iraqi patients

Abstract: The high rates and the patterns of LAIP particularly in Iraqi B-ALL patients may allow the development of more cost-effective strategies for MRD monitoring.

Cited by 11 publications

References 33 publications

CD34 is not Expressed by Blasts in a Third of B-ALL Patients and its Negativity is associated with Aberrant Marker Expression: A Retrospective Analysis

CD34 is not Expressed by Blasts in a Third of B-ALL Patients and its Negativity is associated with Aberrant Marker Expression: A Retrospective Analysis

Targeting CD38 for acute leukemia

Approach to the Adult Acute Lymphoblastic Leukemia Patient

Contact Info

Product

Resources

About